Daily FNArena News - Small Caps

Profit season brings out the best and worst in small caps, and sometimes both at once, reports The New Criterion’s Tim Boreham

A disappointing update on recently acquired powercloud does not ruin the investment case for Hansen Technologies, analysts say

While Data3#’s earnings result confirmed its January trading update, the market was not impressed with how profit growth was achieved

Run-of-the-mill accounting software company Reckon may be set for a re-rating, brokers believe

Artificial intelligence and some valuable experiences should benefit heart device developer Artrya, Tim Boreham explains

Some cannabis gems are sprouting in the ASX weed patch, but they are hard to find in the haze of hype, Tim Boreham, Editor, The New Criterion reports

In response to a broker’s negative assessment, Judo Capital has provided a surprise trading update that significantly exceeded expectations

Brokers raise valuations for Neuren Pharmaceuticals following positive Phase 2 clinical trial results

Tim Boreham highlights the prospects for cancer treatment biotech Imugene

Despite higher interest rates, Autosports Group is seeing no easing in demand for luxury cars, providing solid revenue growth guidance at its AGM